zafirlukast + sulfinpyrazone

**Zafirlukast + sulfinpyrazone** is a combination of two small molecule drugs: zafirlukast, a selective leukotriene receptor antagonist used for the prophylaxis and chronic treatment of asthma by blocking cysteinyl leukotriene receptors (CysLT1) to reduce airway constriction, mucus buildup, and inflammation; and sulfinpyrazone, a uricosuric agent employed in managing chronic gout by competitively inhibiting uric acid reabsorption in the proximal tubule, thereby promoting its urinary excretion and lowering serum urate levels. No established clinical product or specific indication exists for this exact combination, though drug interaction data notes sulfinpyrazone may decrease zafirlukast metabolism via CYP inhibition.[1][3]